← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Acepre, Llc
Columbia, SC
$3,959,636
Total funding
9
Grants
Funding over time
peak $1.6M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,959,636 · 9
By mechanism
R41$2,689,280 · 7
UT1$918,358 · 1
R43$351,998 · 1
Investigators at Acepre, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Develop a novel strategy to deliver N-acetylcysteine for AD treatment$499,441
R41 · FY2024 · AG
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy$461,518
UT1 · FY2024 · AA
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy$456,840
UT1 · FY2023 · AA
A novel polymer-metal nanocomplex for ovarian cancer treatment$392,803
R41 · FY2021 · CA
Use novel natural compound Sparstolonin B to treat bacterial sepsis$300,000
R41 · FY2021 · AI
Development of Dietary Quercetin to Treat Muscle Wasting Disorders$299,998
R43 · FY2020 · AT
Targeting macrophage maladaptation for bacterial sepsis treatment$299,982
R41 · FY2023 · AI
Develop natural compound emodin as a novel therapy for calcific aortic valve disease$299,953
R41 · FY2024 · HL
The development of a multifunctional nanoenzyme for AD treatment$299,628
R41 · FY2022 · AG
Targeting macrophage maladaptation for bacterial sepsis treatment$297,328
R41 · FY2024 · AI
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil$261,212
R41 · FY2018 · AT
Development of Dietary Quercetin to Treat Muscle Wasting Disorders$52,000
R43 · FY2021 · AT
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil$38,933
R41 · FY2019 · AT